Status:
COMPLETED
Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Canada, Inc.
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicentre, observational, non-interventional, retrospective analysis by chart review.
Detailed Description
This study will compare differences in patient and graft related outcomes in renal transplant recipients followed in regional transplant centers versus satellite clinics.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient is at least 18 months post transplant
- Patient had the current transplant during the period 1 July 1997 to no less than 18 months prior to chart review
- Patient is currently on tacrolimus/MMF or AZA - or cyclosporine/MMF or AZA based immunosuppressive therapy
- Patient is not a recipient of dual kidney or multi -organ transplant
- Patient has a functioning graft (i.e. patient does not require dialysis)
- Patient is recipient of a renal transplant including living or cadaveric, related or non-related, or pediatric en bloc kidneys, but excluding kidney-pancreas transplant recipients
- Patient received the current transplant at one of six identified regional transplant centers
- Patient is currently followed in a regional or satellite community based nephrology clinic
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT00902980
Start Date
April 1 2005
End Date
December 1 2006
Last Update
September 18 2014
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
New Westminster, British Columbia, Canada, V3L3W4
2
Vancouver, British Columbia, Canada, V5Z1M9
3
Moncton, New Brunswick, Canada, E1C2Z3
4
Saint John, New Brunswick, Canada, E2L4L2